Biotechnology M&A » By The Online Investor Staff, updated Fri., Apr. 26, 11:30 AM
Recent mergers and acquisitions in the Biotechnology M&A category.
| This Slide: #79 of 83 |
Slide #79. ProStrakan Group plc — GTx, Inc.
Acquirer:
ProStrakan Group plc
Acquiree:
GTx, Inc. (GTXI)
Details:
GTx, Inc. announced that it has sold to ProStrakan Group plc (ProStrakan) its rights and related assets in the metastatic breast cancer product, Fareston, for total cash consideration of $21.7 million. After deducting cash expenses relating to the transaction, GTx will receive net cash proceeds from the sale of approximately $19 million. Fareston (toremifene citrate) 60 mg tablets is a selective estrogen receptor modulator approved in the United States for the treatment of metastatic breast cancer in postmenopausal women.
Open the GTXI Page at The Online Investor »
|
|||||||||
Open the GTXI Page at The Online Investor (in a new window) »
 Free GTXI Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
|
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
